Last reviewed · How we verify
Placebo 2-weeks
Placebo produces no pharmacological effect and serves as a control comparator in clinical trials.
At a glance
| Generic name | Placebo 2-weeks |
|---|---|
| Sponsor | Merz North America, Inc. |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
Placebo is an inert substance used in phase 3 clinical trials to establish baseline efficacy and safety of an investigational drug through comparison against a non-active control. The placebo arm allows researchers to distinguish true drug effects from natural disease progression, spontaneous remission, and psychological expectation effects (placebo response).
Approved indications
Common side effects
Key clinical trials
- The Effects of Resistance Training and a Plant-Based Supplement on Perimenopausal Symptoms and Muscle Health. (NA)
- Efficacy of Nigella Sativa (Nisatol®) in Women With Borderline Blood Pressure Values or a Non-Dipper Blood Pressure Phenotype (NA)
- Effects of Positive Psychological Group Psychotherapy and Auricular Acupressure on Withdrawal Symptoms (NA)
- Psilocybe Cubensis Mushrooms With or Without Fluoxetine for Refractory Depression (PHASE1, PHASE2)
- Phase IIb Clinical Trial for the Efficacy and Safety by CU01-1001 for 24 Weeks in Type 2 DM Patients With Albuminuria (PHASE2)
- Toddler Biomarker of Nutrition Study (NA)
- Effectiveness of Combined Super Inductive System (SIS) Therapy With Therapeutic Exercise and Health Education in Lateral Elbow Tendinopathy (NA)
- Tirzepatide in MetALD (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo 2-weeks CI brief — competitive landscape report
- Placebo 2-weeks updates RSS · CI watch RSS
- Merz North America, Inc. portfolio CI